Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Xcelerate Inc.
- Market Cap
- Unavailable
- Volume
- 98.4K
Quote data as of 7:08 AM ET
About
Xcelerate Inc. specializes in sourcing and integrating engineering expertise and patents, which it then applies to nascent medical technology ventures. The firm's offerings are subsequently deployed within regulated clinical settings for rigorous evaluation, validation, and real-world implementation. Beyond this, the company oversees a comprehensive, full-spectrum approach to medical technology creation and deployment. Established in 1996, the Mauldin, South Carolina-based entity was previously known as Union Dental Holdings, Inc. before rebranding as Xcelerate Inc.
Quick stats
Shares outstanding—
Computed float193.1M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryMedical - Care Facilities
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001138586
Websitehttps://www.xcelerate.global
AI Summary
AI-generated15d agominorbullishoperations updateXcelerate Announces Progress on Medical Deployment Program in Africa
Xcelerate reported progress on its AfiyaSasa Africa healthcare program, transitioning from system integration to preparation for clinical validation in Tanzania.
The company anticipates onboarding its first clinical patients during the third quarter of 2026, supported by the localization of the AdviNOW platform and the integration of Anthropic AI medical reasoning capabilities.
Simultaneously, Xcelerate advanced its patent portfolio by completing the formal assignment process for two U.S. patents related to treating ulcers and viral infections.